Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are ‘fit’ or ‘unfit’ for IC. We compared outcomes of older patients with ne...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Hematol
Auteurs principaux: Maiti, Abhishek, Qiao, Wei, Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., Jabbour, Elias J., Daver, Naval G., Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry A., Montalbano, Kathryn S., Pemmaraju, Naveen, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven M., Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Masarova, Lucia, Thompson, Philip A., Rausch, Caitlin R., Ning, Jing, Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128145/
https://ncbi.nlm.nih.gov/pubmed/33264443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26061
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires